Deliver us from aging – the Quicksilver method

Bigger certainly doesn't mean better when it comes to Quicksilver's nutraceutical delivery methods.

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Bigger certainly doesn’t mean better when it comes to Quicksilver’s nutraceutical delivery methods.

The COVID-19 pandemic has caused an upturn in the supplements industry; from enhanced immunity to general wellness, there are shelves of tablets, powers and unguents that promise various benefits. One company caught our eye recently – Quicksilver Scientific, which is based in Louisville, Colorado. There is nothing mercurial about Quicksilver’s push for the best bioavailability it can offer, using its own specially-developed nanoparticle technology to deliver antiaging nutraceuticals.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Evommune bets $30m upfront on a new autoimmune drug

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE